TY - JOUR
T1 - Long-Term Metabolic Outcomes after Gestational Diabetes Mellitus (GDM)
T2 - Results from the Odense GDM Follow-Up Study (OGFUS)
AU - Jacobsen, Kristine Hovde
AU - Aalders, Jori
AU - Sølling, Katrine
AU - Andersen, Marianne Skovsager
AU - Christensen, Maria Hornstrup
AU - Vinter, Christina Anne
AU - Højlund, Kurt
AU - Jensen, Dorte Møller
N1 - Copyright © 2022 Kristine Hovde Jacobsen et al.
PY - 2022
Y1 - 2022
N2 - Aims: To compare metabolic profiles and the long-term risk of metabolic dysfunction between women with previous gestational diabetes mellitus (pGDM) and women without pGDM (non-GDM) matched on age, prepregnancy body mass index (BMI), and parity.Methods: In total, 128 women with pGDM (median follow-up: 7.8 years) and 70 non-GDM controls (median follow-up: 10.0 years) completed a 2 h oral glucose tolerance test (OGTT) with assessment of glucose, C-peptide, insulin, and other metabolic measures. Additionally, anthropometrics, fat mass, and blood pressure were assessed and indices of insulin sensitivity and beta cell function were calculated.Results: The prevalence of type 2 diabetes mellitus (T2DM) was significantly higher in the pGDM group compared to the non-GDM group (26% vs. 0%). For women with pGDM, the prevalence of prediabetes (38%) and the metabolic syndrome (MetS) (59%) were approximately 3-fold higher than in non-GDM women (
p'
s < 0.001). Both insulin sensitivity and beta cell function were significantly reduced in pGDM women compared to non-GDM women.
Conclusion: Despite similar BMI, women with pGDM had a substantially higher risk of developing T2DM, prediabetes, and the MetS compared to controls. Both beta cell dysfunction and reduced insulin sensitivity seem to contribute to this increased risk.
AB - Aims: To compare metabolic profiles and the long-term risk of metabolic dysfunction between women with previous gestational diabetes mellitus (pGDM) and women without pGDM (non-GDM) matched on age, prepregnancy body mass index (BMI), and parity.Methods: In total, 128 women with pGDM (median follow-up: 7.8 years) and 70 non-GDM controls (median follow-up: 10.0 years) completed a 2 h oral glucose tolerance test (OGTT) with assessment of glucose, C-peptide, insulin, and other metabolic measures. Additionally, anthropometrics, fat mass, and blood pressure were assessed and indices of insulin sensitivity and beta cell function were calculated.Results: The prevalence of type 2 diabetes mellitus (T2DM) was significantly higher in the pGDM group compared to the non-GDM group (26% vs. 0%). For women with pGDM, the prevalence of prediabetes (38%) and the metabolic syndrome (MetS) (59%) were approximately 3-fold higher than in non-GDM women (
p'
s < 0.001). Both insulin sensitivity and beta cell function were significantly reduced in pGDM women compared to non-GDM women.
Conclusion: Despite similar BMI, women with pGDM had a substantially higher risk of developing T2DM, prediabetes, and the MetS compared to controls. Both beta cell dysfunction and reduced insulin sensitivity seem to contribute to this increased risk.
KW - Diabetes Mellitus, Type 2/epidemiology
KW - Diabetes, Gestational
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Insulin/therapeutic use
KW - Insulin Resistance
KW - Metabolic Syndrome/epidemiology
KW - Prediabetic State/epidemiology
KW - Pregnancy
U2 - 10.1155/2022/4900209
DO - 10.1155/2022/4900209
M3 - Journal article
C2 - 35789592
SN - 2314-6745
VL - 2022
JO - Journal of Diabetes Research
JF - Journal of Diabetes Research
M1 - 4900209
ER -